After a first asthma exacerbation, most patients do not progress — and you can tell which ones might

Design

observational cohort study using Danish registry data from the NORDSTAR platform, patients identified 2000-2018 and followed five years, multivariable logistic regression

Population

99,748 adults with mild-to-moderate asthma experiencing their first asthma exacerbation

Primary outcome

progression to severe asthma by ERS/ATS criteria within five years

Effect

4.1% progressed; exacerbation despite medium-dose ICS OR 3.72 (95% CI 3.39-4.09); eosinophils >=0.6 x10^9/L OR 1.97 (1.47-2.61); highest-risk profile 30.4%

This cohort used Danish registry data within the NORDSTAR collaboration to follow 99,748 adults with mild-to-moderate asthma from their first exacerbation, for five years, looking for progression to severe asthma by ERS/ATS criteria. The reassuring headline is that 4.1% progressed.

The useful part is the risk profile. Exacerbating despite medium-dose inhaled corticosteroid carried by far the strongest association (OR 3.72, 95% CI 3.39 to 4.09), followed by blood eosinophils at or above 0.6 x 10^9/L (OR 1.97, 95% CI 1.47 to 2.61), high short-acting beta agonist use (OR 1.76, 95% CI 1.64 to 1.90), two or more respiratory infections (OR 1.61, 95% CI 1.49 to 1.73), and age 40 to 49 (OR 1.62, 95% CI 1.49 to 1.77). Combined, they matter a great deal: a patient in their forties with late-onset eosinophilic asthma on medium-dose inhaled corticosteroid and recurrent respiratory infections had a 30.4% five-year risk.

This is observational and cannot say that identifying these patients early changes anything — the authors are explicit that whether early recognition modifies the risk is unknown. What it legitimately supports is triage: an eosinophil count and an inhaler-use review at the visit after a first exacerbation costs almost nothing and separates a 4% background risk from a 30% one. The Danish registry population is also not an Indian clinic population, and the exposure to air pollution and to untreated respiratory infection differs, so treat the profile as a shape rather than a calibrated probability.

• Check a blood eosinophil count at the review after a first exacerbation, not only in established severe asthma
• Record whether the exacerbation happened despite medium-dose inhaled corticosteroid — the single strongest marker
• Count reliever canisters; high short-acting beta agonist use is both a risk marker and a modifiable one
• Ask about respiratory infection frequency; two or more raised the risk meaningfully
• Do not present the 30.4% figure to a patient as their personal risk — it is a profile from a Danish registry, not a validated calculator

The statistics, in plain English

These are odds ratios from multivariable logistic regression, so each is adjusted for the others — but adjustment only removes confounding by variables that were measured, and registry data measure prescriptions rather than adherence. The confidence intervals are tight because the cohort is very large, which makes the estimates precise without making them causal. The 30.4% profile risk comes from combining several factors in a model, not from observing a group of such patients directly, so it will be less accurate than the individual odds ratios that built it.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.